Home Healthy

Healthy

Dupixent: FDA Approves First and Only Medicine for Allergic Fungal Rhinosinusitis in Adults and Children Ages 6 Years and Older

— September 23, 2026 in Healthy
Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved Dupixent for treating adults and children (ages 6 years and… Read more

Adquey: FDA Approves New Nonsteroidal Ointment for Mild to Moderate Eczema

— September 23, 2026 in Healthy
Adquey (difamilast 1%) is a prescription ointment the FDA has approved for adults and for children 2 and older who have mild to moderate atopic dermatitis (AD), often called eczema. It is a nonsteroidal medicine… Read more

FDA Approves Once-Daily Wegovy Pill as the First Oral GLP-1 Medicine for Weight Loss in Adults With Obesity or Overweight

— September 23, 2026 in Healthy
Wegovy (semaglutide) is a prescription medicine that helps with weight loss and lowers the risk of heart problems and liver disease. The FDA has approved its oral pill form to be used alongside a low-calorie… Read more

Fasenra: FDA Approves Under-the-Skin Shot to Help Reduce Flares in Hypereosinophilic Syndrome

— September 23, 2026 in Healthy
Fasenra (benralizumab), a targeted medicine called a monoclonal antibody, binds to and reduces levels of eosinophils, a type of immune cell that can cause inflammation. This can ease symptoms in people with eosinophil-driven conditions. First… Read more

Imfinzi: FDA Approves Immunotherapy Plus BCG Combination for High-Risk Early Non-Muscle-Invasive Bladder Cancer

— September 23, 2026 in Healthy
Imfinzi (durvalumab) is a prescription immunotherapy medicine used to treat different types of cancer. The FDA has approved the combination of Imfinzi and Bacillus Calmette-Guérin (BCG) therapy to treat a high-risk, early form of bladder… Read more

Tecentriq and Tecentriq Hybreza: FDA Approves First ctDNA‑Guided Adjuvant Immunotherapies to Target Residual Muscle‑Invasive Bladder Cancer After Surgery

— September 23, 2026 in Healthy
Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) are prescription immunotherapy medicines used to help the body’s immune system fight cancer. The FDA has now approved them to treat muscle-invasive bladder cancer (MIBC) in adults after… Read more

Beqalzi: FDA Approves New Oral BCL-2 Blocker for Relapsed or Refractory Mantle Cell Lymphoma

— September 23, 2026 in Healthy
Beqalzi (sonrotoclax) is a prescription, targeted, oral cancer medicine that has received accelerated FDA approval for treating adults with mantle cell lymphoma (MCL) that has relapsed or become resistant after at least two prior treatments,… Read more

Inqovi: FDA Approves First All‑Oral Regimen for Certain Patients With Newly Diagnosed Acute Myeloid Leukemia

— September 23, 2026 in Healthy
Inqovi is a fixed‑dose oral pill that contains two medicines, decitabine and cedazuridine. The FDA has approved using Inqovi along with another oral pill, venetoclax, for treating newly diagnosed acute myeloid leukemia (AML) in adults… Read more

Hympavzi: Once‑Weekly, Single‑Dose Under‑the‑Skin Shot to Help Prevent Bleeding in Hemophilia A or B (ages 6+)

— September 23, 2026 in Healthy
Hympavzi (marstacimab‑hncq) is a preventive medicine you take as a once‑weekly shot under the skin. It is used in adults and in children 6 and older with hemophilia A or hemophilia B, whether or not… Read more

Parsol Shield: FDA Approves New Sunscreen Active Ingredient for Broad UV Protection

— September 23, 2026 in Healthy
Bemotrizinol is a sunscreen active ingredient that helps protect your skin from ultraviolet A (UVA) and ultraviolet B (UVB) rays. Parsol Shield is expected to be the first sunscreen available with this ingredient. The FDA… Read more